TITLE

FDA drug safety bill one step

PUB. DATE
July 2007
SOURCE
Drug Topics;7/23/2007, Vol. 151 Issue 14, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the U.S. House of Representatives' passage of the bill that would give the Food and Drug Administration (FDA) more authority to ensure drug safety by requiring pharmaceutical industries to perform post-marketing surveillance studies, demand more user fees and other measures. The article also mentions that a conference committee will have to come up with a bill that both the Senate and the House can approve before it is submitted to U.S. President George W. Bush for signature.
ACCESSION #
26131612

 

Related Articles

  • DTC REPORT: Update.  // Medical Marketing & Media;Nov2007, Vol. 42 Issue 11, p28 

    The article offers news briefs related to the pharmaceutical industry in the U.S. President George W. Bush has signed the Food and Drug Administration (FDA) Amendments Act that limits drug advertising to consumers. Eli Lilly & Co. has stated that they can increase their consumer advertising by...

  • PDUFA. Kracov, Daniel // Pharmaceutical Executive;Sep2007, Vol. 27 Issue 9, p62 

    The article offers a guide to Prescription Drug User Fee Act (PDUFA IV), which is pending in U.S. Congress. It focuses on the details on the many provisions the two bills, the Senate Food and Drug Administration (FDA) Act and the House FDA Amendments Act, have in common, as well as the...

  • Implementing FDA Bill Could Be Complex And Challenging. Young, Donna // BioWorld Today;9/28/2007, Vol. 18 Issue 189, p2 

    The article looks at the effects of the passage of the U.S. Food and Drug Administration (FDA) Amendments act, signed by President George W. Bush in 2007. The law reportedly widens the scope of the post-marketing monitoring power of FDA, tripling its budget for such activities. It also...

  • New legislation puts clinical trials in US "public arena.".  // PharmacoEconomics & Outcomes News;11/3/2007, Issue 540, p14 

    The article reports on the U.S. Food and Drug Administration (FDA) Revitalisation Act which was signed into law by President George W. Bush in 2007. It cites that the legislation aims to strengthen the regulatory authority of the agency, thereby ensuring the safety of drugs and medical devices...

  • FY 2008 Funding Increases. Rios, Maribel // Pharmaceutical Technology;Feb2008, Vol. 32 Issue 2, p26 

    The article reports on the bill HR 2764 signed by President George W. Bush for appropriations to the U.S. Food and Drug Administration (FDA) during fiscal year 2008. The law, which allocates more than $1.7 billion, bans FDA from utilizing the funding for the agency's Reagan-Udall Foundation....

  • New legislation puts clinical trials in US "public arena.".  // Reactions Weekly;11/3/2007, Issue 1176, p1 

    The article concerns the Food and Drug Administration (FDA) Revitalization Act signed into law by U.S. President George W. Bush. The law enables the FDA to request the completion of safety studies after drug marketing when deemed necessary, the alteration of drug labels to reflect new...

  • BUSH ADMINISTRATION TORT REFORM PROPOSALS. Getty, J. Paul // Electronic Ardell Wellness Report (E-AWR);5/6/2005, Issue 282, p12 

    The article focuses on the proposals by President George W. Bush administration' reform efforts. When drug companies are sued for complications arising from previously unknown adverse product side effects, the situation seems quite unfair, in that the company jumped all the hoops required to...

  • As I See It. Dickinson, James G. // Medical Marketing & Media;Apr2008, Vol. 43 Issue 4, p16 

    The author reflects on the need for U.S. President George W. Bush's administration to settle product liability issues in the pharmaceutical industry. He claims that their failure to address the issue would give the Democratic administration an opportunity to reverse Republicans' previous...

  • As I See It. Dickinson, James G. // Medical Marketing & Media;Dec2007, Vol. 42 Issue 12, p14 

    The article relates the author's perspective concerning U.S. President George W. Bush administration's agenda related to the pharmaceuticals industry. The author asserts that the Bush administration's agenda has brought a not-so-conservative results for drug marketers. Among these agenda which...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics